Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.
Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.
复制标题
纳米颗粒介导的化疗药物和 siRNA 的联合递送用于癌症联合治疗
DOI：
10.1080/17425247.2016.1205583
复制
发表时间：
2017-01
影响因子：
6.6
通讯作者：
Merlin D
中科院分区：
文献类型：
--
作者：
Xiao B;Ma L;Merlin D
摘要简介：癌症是全球主要的死亡原因。目前临床上的癌症治疗主要包括化疗、放疗和手术，其中化疗是最常见的。涵盖的领域：基于单一“魔术子弹”概念的癌症治疗通常与有限的治疗效果、不必要的副作用和耐药性相关。由于多种药物的协同或累加效应，多种药物的组合是有效治疗癌症的有希望的策略。小干扰RNA（siRNA）具有敲低致癌基因或药物外排转运蛋白基因表达的能力，为癌症治疗铺平了道路。基于纳米颗粒（NP）介导的共递送的化疗剂和siRNA治疗是联合癌症治疗的有前景的方法。专家意见：用于癌症治疗的化学治疗剂和siRNA的组合提供了增强治疗功效、减少副作用和克服耐药性的潜力。化学药物和siRNA在同一NP中的共递送在癌症治疗中将比单独应用化学试剂或siRNA有效得多。随着材料科学的发展，纳米颗粒已经成为最广泛使用的化疗药物和siRNA共递送平台。
ABSTRACT Introduction: Cancer is the leading cause of death worldwide. Current cancer treatments in the clinic mainly include chemotherapy, radiotherapy and surgery, with chemotherapy being the most common. Areas covered: Cancer treatments based on the single ‘magic-bullet’ concept are often associated with limited therapeutic efficacy, unwanted adverse effects, and drug resistance. The combination of multiple drugs is a promising strategy for effective cancer treatment due to the synergistic or additive effects. Small interfering RNA (siRNA) has the ability to knock down the expression of carcinogenic genes or drug efflux transporter genes, paving the way for cancer treatment. Treatment with both a chemotherapeutic agent and siRNA based on nanoparticle (NP)-mediated co-delivery is a promising approach for combination cancer therapy. Expert opinion: The combination of chemotherapeutic agents and siRNAs for cancer treatment offers the potential to enhance therapeutic efficacy, decrease side effects, and overcome drug resistance. Co-delivery of chemical drug and siRNA in the same NP would be much more effective in cancer therapy than application of chemical agent or siRNA alone. With the development of material science, NPs have come to be the most widely used platform for co-delivery of chemotherapeutic drugs and siRNAs.
登录
查看更多内容
影响因子：
13.3
作者：
Chen, Alex M.;Zhang, Min;Wei, Dongguang;Stueber, Dirk;Taratula, Oleh;Minko, Tamara;He, Huixin
通讯作者：
He, Huixin
影响因子：
62.1
作者：
Kamaly N;Yameen B;Wu J;Farokhzad OC
通讯作者：
Farokhzad OC
使用免疫脂质体共同递送阿霉素和核糖核苷酸还原酶 M2 siRNA 抑制肝细胞癌生长
影响因子：
14
作者：
Gao, Jie;Chen, Huaiwen;Guo, Yajun
通讯作者：
Guo, Yajun
影响因子：
78.5
作者：
Chabner, BA;Roberts, TG
通讯作者：
Roberts, TG
影响因子：
64.8
作者：
Castanotto, Daniela;Rossi, John J.
通讯作者：
Rossi, John J.